Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation

Neurogastroenterology and Motility

Volumn 20, Issue 2, 2008, Pages 134-141

  Sabate J M ^a,b,c   Bouhassira, D ^b,c   Poupardin, C ^a   Wagner, A ^d   Loria, Y ^e   Coffin, B ^a,b,c  

^a HÔPITAL LOUIS MOURIER   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NOVARTIS PHARMA K K   (Japan)

Author keywords

Abdominal pain; Constipation predominant irritable bowel syndrome; RIII reflex; Tegaserod

Indexed keywords

PLACEBO; TEGASEROD;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLEXOR REFLEX; HEADACHE; HUMAN; INTESTINE SOUND; IRRITABLE COLON; NAUSEA; NOCICEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY EVALUATION; SIDE EFFECT; XEROSTOMIA;

ADULT; COMPLIANCE; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MANOMETRY; MIDDLE AGED; PLACEBOS; RECTUM; REFLEX; SEROTONIN AGONISTS;

EID: 38149133878     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.01030.x     Document Type: Article

References (26)

1. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead W. Rome II: The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA : Degnon Associates, 2000.
2. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002 122 : 2032 48.
3. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995 109 : 40 52.
4. Bouhassira D, Chollet R, Coffin B et al. Inhibition of a somatic nociceptive reflex by gastric distention in humans. Gastroenterology 1994 107 : 985 92.
5. Coffin B, Bouhassira D, Chollet R et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 1996 10 : 919 25.
6. Bouhassira D, Sabate JM, Coffin B, Le Bars D, Willer JC, Jian R. Effects of rectal distensions on nociceptive flexion reflexes in humans. Am J Physiol 1998 275 : G410 7.
7. Sabate JM, Coffin B, Jian R, Le Bars D, Bouhassira D. Rectal sensitivity assessed by a reflexologic technique: further evidence for two types of mechanoreceptors. Am J Physiol Gastrointest Liver Physiol 2000 279 : G692 9.
8. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003 17 : 577 85.
9. Coffin B, Bouhassira D, Sabate JM, Barbe L, Jian R. Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 2004 53 : 1465 70.
10. Willer JC. Comparative study of perceived pain and nociceptive flexion reflex in man. Pain 1977 3 : 69 80.
11. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001 15 : 277 89.
12. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 66.
13. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002 16 : 1877 88.
14. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003 52 : 671 6.
15. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004 39 : 119 26.
16. Tack J, Muller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 2005 54 : 1707 13.
17. Schikowski A, Thewissen M, Mathis C, Ross HG, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002 14 : 221 7.
18. Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004 53 : 1595 601.
19. Millan MJ. Descending control of pain. Prog Neurobiol 2002 66 : 355 474.
20. Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 1979 6 : 283 304.
21. Willer JC, Roby A, Le Bars D. Psychophysical and electrophysiological approaches to the pain-relieving effect of heterotopic nociceptive stimuli. Brain 1984 107 : 1095 112.
22. Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the involvement of serotonergic mechanisms in diffuse noxious inhibitory controls (DNIC). Brain Res 1982 236 : 329 37.
23. Kraus E, Besson JM, Le Bars D. Behavioral model for diffuse noxious inhibitory controls (DNIC): potentiation by 5-hydroxytryptophan. Brain Res 1982 231 : 461 5.
24. De Broucker T, Cesaro P, Willer JC, Le Bars D. Diffuse noxious inhibitory controls in man. Involvement of the spinoreticular tract. Brain 1990 113 : 1223 34.
25. Price DD, Craggs J, Verne GN, Perlstein WM, Robinson ME. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 2007 127 : 63 72.
26. Kellow JE, Azpiroz F, Delvaux M et al. Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology 2006 130 : 1412 20.